MIGENIX Inc. (TSE: MGI) has proven and demonstrated that using the oral alpha-glucosidase inhibitor, celgosivir (MX-3253), in combination with pegylated interferon and ribavirin is more beneficial compared to treatment with pegylated interferon and ribavirin alone in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated interferon plus ribavirin.
This particular group is considered as one of the most difficult to treat HCV patient populations.
According to Jim DeMesa, M.D., President and CEO of MIGENIX:
"The top-line results from this study are very encouraging and validate our development program by demonstrating proof-of-concept of celgosivir in combination with pegylated interferon and ribavirin, with the goal of improving the treatment outcome for patients who currently have few effective therapeutic options.
This, along with our preclinical data showing strong synergy between celgosivir and other anti-HCV drugs currently in development, makes us optimistic about the future potential of this first-in-class compound.
With the completion of this non-responder trial, we will be working to provide a full data package to Schering-Plough over the next month for their exclusive review under our License Option Agreement and to complete our celgosivir combination Phase II study in treatment-naive patients, a clinical trial which began enrolling patients last month."
The top line clinical data came from a Phase II study.
Find more details of the clinical data from the press release (a pdf file).
Comment Preview